STOCKHOLDER'S EQUITY | Stock Grants None. Restricted Stock Units: The Company issued 500,000 restricted stock units to certain employees in fiscal 2018. 250,000 units were forfeited in 2019 due to the termination of an employee. The Company is accounting for the stock compensation for the restricted shares using ASC 718 Compensation-Stock Compensation. The restricted stock vests on the two-year anniversary of the date of grant and the employee needs to still be employed at the time of vesting to receive the grant. The Company uses the Black Scholes calculation to determine the expense and records the expense over the life of the vesting period of each grant. The Company recorded approximately $1,000 and $2,000 in stock compensation expense in fiscal 2019 and 2018, respectively, in relation to these grants. The Company entered into an employment agreement with its Chief Revenue Officer, Mr. Todd Sherin, that included the granting of 5,000,000 restricted shares that vest over a three-year period and included meeting certain performance obligations. The Company is accounting for the stock compensation for the restricted shares using ASC 718 Compensation-Stock Compensation, specifically ASC 718-10-30-28, 718-10-55-10, and 718-10-55-61. Pursuant to these guidelines the Company is not obligated to record compensation expense until the point in time at which it is probable that Mr. Sherin would meet the performance obligation set forth in the agreement. At such time, the Company would record compensation expense by multiplying the amount of shares vesting at that point by the stock price on the effective date of the agreement. As of December 31, 2019, the Company determined that the probability of meeting these obligations was minimal and as such has not recorded any stock compensation expense for this restricted stock grant. Stock Options In 2007, the Board of Directors approved the 2007 Cicero Employee Stock Option Plan which permits the issuance of incentive and nonqualified stock options, stock appreciation rights, performance shares, and restricted and unrestricted stock to employees, officers, directors, consultants, and advisors. The aggregate number of shares of common stock which may be issued under this Plan shall not exceed 4,500,000 shares upon the exercise of awards and provide that the term of each award be determined by the Board of Directors. The Company also has a stock incentive plan for outside directors and the Company has set aside 1,200 shares of common stock for issuance under this plan. Under the terms of the Plans, the exercise price of the stock options may not be less than the fair market value of the stock on the date of the award and the options are exercisable for a period not to exceed ten years from date of grant. Stock appreciation rights entitle the recipients to receive the excess of the fair market value of the Company's stock on the exercise date, as determined by the Board of Directors, over the fair market value on the date of grant. Performance shares entitle recipients to acquire Company stock upon the attainment of specific performance goals set by the Board of Directors. Restricted stock entitles recipients to acquire Company stock subject to the right of the Company to repurchase the shares in the event conditions specified by the Board are not satisfied prior to the end of the restriction period. The Board may also grant unrestricted stock to participants at a cost not less than 85% of fair market value on the date of sale. Options granted vest at varying periods up to five years and expire in ten years. The plan expired in fiscal 2017 and as such no further options are available to grant. Activity for stock options issued under these plans for the years ending December 31, 2019 and 2018 was as follows: Number of Options Option Price Per Share Weighted Average Exercise Price Aggregate Intrinsic Value Balance at December 31, 2017 1,577,750 0.05-0.51 $ 0.08 Granted -- -- -- Forfeited (796,539 ) 0.05-0.09 $ 0.07 Expired (75,000 ) 0.23 $ 0.23 Balance at December 31, 2018 706,211 0.05-0.11 $ 0.08 Granted -- -- -- Forfeited -- -- -- Expired (25,000 ) 0.11 $ 0.11 Balance at December 31, 2019 681,211 0.05-0.11 $ 0.08 $ 0.00 There was no activity for non-vested stock options under these plans for the fiscal year ending December 31, 2019 and 2018. There were no options granted in 2019 and 2018. At December 31, 2019, there was no unrecognized compensation cost related to stock options. At December 31, 2019 and 2018, options to purchase 681,211 and 706,211 shares of common stock were exercisable, respectively, pursuant to the plans at prices ranging from $0.05 to $0.11 . The following table summarizes information about stock options outstanding at December 31, 2019: Exercise Price Number Outstanding Remaining Contractual Life for Options Outstanding Number Exercisable Weighted Average Exercise Price $ 0.05-0.06 203,461 2.7 203,641 $ 0.06 0.07-0.09 452,750 0.6 452,750 0.09 0.10-0.11 25,000 1.4 25,000 0.10 681,211 1.3 681,211 $ 0.08 Preferred Stock On March 26, 2019, the Company entered into agreement with John L. Steffens, the Chairman of the Board of Directors, to convert $3,891,500 of principal amount of debt and $358,697 of interest into 4,250 shares of the Company’s Series A Preferred Stock. Per the Certificate of Designation, the initial conversion of preferred stock to common equaled 85,003,934 shares of common stock of the Company at a price of $0.05 per share, subject to adjustment for stock dividends, stock splits and similar events. Additionally, Mr. Steffens was granted a warrant for 17,000,787 of the Company’s common shares at a price of $0.05 per share. The Company accounted for the transaction pursuant to Topic ASC 470-50, Modification and Extinguishment of Debt. Due to the fact that the transaction was with Mr. Steffens, the Company’s Chairman of the Board, the Company determined that this was not an arm’s length agreement and as such has recorded the entire transaction through additional paid in capital. Series A The Series A Preferred Stock ranks senior in preference and priority to the Company’s common stock with respect to dividend and liquidation rights and, except as provided in the Certificate of Designation or otherwise required by law, will vote with the common stock on an as converted basis on all matters presented for a vote of the holders of common stock, including directors. The Series A Preferred Stock is convertible at any time at the option of the holder at an initial conversion ratio of 20,000 shares of Common Stock for each share of Series A Preferred Stock. The initial conversion ratio shall be adjusted in the event of any stock splits, stock dividends and other recapitalizations. The holders of the Series A Preferred Stock are entitled to a liquidation preference of $1,000 per share of Series A Preferred Stock plus any declared but unpaid dividends upon the liquidation of the Company. The Series A Preferred Stock may be redeemed by the Company at any time and must be redeemed by the Company, upon the written request of the holders of at least a majority of the then outstanding shares of Series A Preferred Stock, after the occurrence of one of the following events: (x) the Company’s trailing 12 month EBITDA exceeds $5,000,000, (y) the sale of all, or substantially all of the assets of the Company, or (z) the sale of all or substantially all the intellectual property of the Company, which in the case of “y” or “z” result in net proceeds to the Company in excess of $6,000,000, at a redemption price equal to $1,000 plus all declared but unpaid dividends, which amount will be paid in three annual installments. The approval of at least two thirds of the holders of Series A Preferred Stock, voting together as a separate class, is required for: (i) the merger, sale of all, or substantially all of the assets or intellectual property, recapitalization, or reorganization of the Company, unless such action (x) results in net proceeds to the stockholders of the Company in excess of $5,000,000, and (y) has received the prior approval of the Board of Directors. (ii) the authorization or issuance of any equity security having any right, preference or priority superior to or on parity with the Series A Preferred Stock. (iii) the redemption, repurchase or acquisition, directly or indirectly, through subsidiaries or otherwise, of any equity securities (other than the redemption of the Series A Preferred Stock) or the payment of dividends or other distributions on equity securities by the Company (other than on the Series A Preferred Stock). (iv) any amendment or repeal of any provision of the Company’s Certificate of Incorporation or Bylaws that would adversely affect the rights, preferences, or privileges of the Series A Preferred Stock. and (v) the liquidation, dissolution or winding up of the business and affairs of the Company, the effectuation of any Liquidation Event (as defined in Certificate of Designation), or the consent to any of the foregoing, unless such action (x) results in net proceeds to the stockholders of the Company in excess of $5,000,000, and (y) has received the prior approval of the Board of Directors. Stock Warrants: The Company values warrants based on the Black-Scholes pricing model. In accordance with ASC 815, these warrants are classified as equity. The warrants were issued in conjunction with certain promissory notes and the private investment in the Company’s shares. At December 31, 2019, there were 37,334,407 exercisable warrants outstanding at an exercise price of $0.05 and $0.07 per share. Number of Warrants Warrant Price Per Share Weighted Average Exercise Price Balance at December 31, 2017 228,004,448 $ 0.04-$0.20 $ 0.05 Issued -- -- -- Exercised -- -- -- Forfeited (207,670,828 ) $ 0.04-$0.20 $ 0.05 Balance at December 31, 2018 20,333,620 $ 0.07 $ 0.07 Issued 17,000,787 $ 0.05 $ 0.05 Exercised -- -- -- Forfeited -- -- -- Balance at December 31, 2019 37,334,407 $ 0.05-$0.07 $ 0.06 Accrued Dividends: The Company reversed approximately $447,000 of accrued dividends associated with previously issued Series B preferred stock in fiscal 2018. The dividends were only payable to current shareholders of Series B if there was a liquidation of the Company or if approved by the Board of Directors. As an automatic conversion of all outstanding Series B preferred stock was approved by the Board of Directors in September 2015, the Company is no longer under any obligation to pay dividends to the former holders of the Series B preferred stock. |